Senti Biosciences (SNTI) News Today $3.32 +0.07 (+2.15%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.32 +0.01 (+0.15%) As of 05/2/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Senti Biosciences (NASDAQ:SNTI) Receives Buy Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $12.00 price target on shares of Senti Biosciences in a report on Friday.May 4 at 8:47 AM | marketbeat.comSenti Biosciences Announces Positive Data for SENTI-202 in Phase 1 Trial at AACR Annual Meeting 2025May 3 at 6:44 PM | nasdaq.comSenti Bio Releases Virtual Investor "What This Means" SegmentMay 3 at 12:08 AM | tmcnet.comSenti Bio Releases Virtual Investor “What This Means” SegmentMay 1 at 9:15 AM | globenewswire.comSenti Bio to Present at the Citizens JMP Life Sciences ConferenceApril 30, 2025 | globenewswire.comSenti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in ...April 29, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIApril 29, 2025 | globenewswire.comSenti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AMLApril 28, 2025 | globenewswire.comSenti Bio to hold a conference callApril 28, 2025 | markets.businessinsider.comSenti Biosciences to Host Conference Call on SENTI-202 Phase 1 Clinical Data Ahead of AACR Annual MeetingApril 26, 2025 | nasdaq.comSenti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ETApril 24, 2025 | globenewswire.comSenti Bio Participates in a Virtual Investor KOL Connect SegmentApril 21, 2025 | globenewswire.comSenti Biosciences, Inc. (NASDAQ:SNTI) Short Interest UpdateSenti Biosciences, Inc. (NASDAQ:SNTI - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 61,500 shares, an increase of 55.3% from the March 15th total of 39,600 shares. Based on an average trading volume of 44,900 shares, the short-interest ratio is currently 1.4 days. Approximately 0.8% of the shares of the company are short sold.April 19, 2025 | marketbeat.comSenti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell SegmentApril 16, 2025 | globenewswire.comSenti Bio appoints James Trager to Scientific Advisory BoardApril 11, 2025 | markets.businessinsider.comSenti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.April 10, 2025 | globenewswire.comSenti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.April 10, 2025 | globenewswire.comSenti Biosciences joins Webull’s Corporate Connect ServiceApril 9, 2025 | uk.investing.comSenti Bio Joins Webull Corporate Connect Service PlatformApril 7, 2025 | globenewswire.comSenti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025April 3, 2025 | globenewswire.comSenti Bio files $300M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comSenti Bio files to sell 52.9M shares of common stock for holdersMarch 21, 2025 | markets.businessinsider.comSenti Biosciences, Inc.: Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate HighlightsMarch 21, 2025 | finanznachrichten.deSenti Bio reports Q4 EPS (67c), consensus ($3.13)March 21, 2025 | markets.businessinsider.comSenti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate HighlightsMarch 20, 2025 | globenewswire.comSenti Bio appoints new board member, grants stock optionsMarch 15, 2025 | investing.comSenti Bio Appoints Feng Hsiung to Board of DirectorsMarch 13, 2025 | globenewswire.comSenti Biosciences Announces Board Changes and Equity Plan UpdateMarch 12, 2025 | investing.comSenti Biosciences Expands Board with New AppointmentMarch 10, 2025 | tipranks.comSenti Bio appoints Jay Cross as CFOFebruary 25, 2025 | msn.comSenti Bio Strengthens Leadership Team with Strategic HiresFebruary 25, 2025 | globenewswire.comSenti Biosciences, Inc. (NASDAQ:SNTI) CEO Sells $15,962.54 in StockFebruary 7, 2025 | insidertrades.comSenti Biosciences executive sells $6,074 in stockFebruary 7, 2025 | msn.comSenti Biosciences CEO Timothy Lu sells shares worth $18,338February 7, 2025 | msn.comSenti Biosciences Renews Consulting Agreement with Yvonne LiFebruary 6, 2025 | tipranks.comSenti Bio Announces Additional $11.5 Million of FinancingJanuary 6, 2025 | markets.businessinsider.comSenti Bio announces first patient dosed in clinical trial of SN301ADecember 17, 2024 | markets.businessinsider.comSenti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest TherapeuticsDecember 16, 2024 | globenewswire.comSenti Biosciences Announces New Employment Inducement GrantsDecember 3, 2024 | globenewswire.comSenti Biosciences Advances with Key Financial and Strategic MovesDecember 2, 2024 | markets.businessinsider.comSenti Biosciences Skyrockets 400% On Oversubscribed PIPE Deal, Promising Cancer Trial Data: Retail OverjoyedDecember 2, 2024 | msn.comWhy Is Senti Biosciences Stock Surging Over 400% On Monday?December 2, 2024 | benzinga.comSenti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity FinancingDecember 2, 2024 | globenewswire.comSenti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AMLDecember 2, 2024 | globenewswire.comSenti Biosciences Faces Financial Challenges Amid Strategic FocusNovember 20, 2024 | markets.businessinsider.comSenti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate HighlightsNovember 14, 2024 | globenewswire.comSenti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Down 14.7% in OctoberSenti Biosciences, Inc. (NASDAQ:SNTI - Get Free Report) saw a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 59,200 shares, a drop of 14.7% from the September 30th total of 69,400 shares. Currently, 2.1% of the company's shares are short sold. Based on an average daily volume of 43,400 shares, the days-to-cover ratio is currently 1.4 days.October 28, 2024 | marketbeat.comSenti Biosciences (NASDAQ:SNTI) Trading 7.8% Higher - Should You Buy?Senti Biosciences (NASDAQ:SNTI) Trading Up 7.8% - Should You Buy?October 8, 2024 | marketbeat.comSenti Biosciences (NASDAQ:SNTI) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comSenti Bio to Participate in Upcoming Investor ConferencesSeptember 3, 2024 | globenewswire.com Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address SNTI Media Mentions By Week SNTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNTI News Sentiment▼0.220.73▲Average Medical News Sentiment SNTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNTI Articles This Week▼101▲SNTI Articles Average Week Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tectonic Therapeutic News Taysha Gene Therapies News Maze Therapeutics News ORIC Pharmaceuticals News COMPASS Pathways News Alpha Teknova News Heron Therapeutics News Autolus Therapeutics News Arcturus Therapeutics News Checkpoint Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNTI) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNTI Stock Free SNTI Stock Alerts